ASNR 2023
Attending ASNR 2023? Stop by booth 603 to learn about our complete solution for the early detection, diagnosis, and management of neurological disorders.
Attending ASNR 2023? Stop by booth 603 to learn about our complete solution for the early detection, diagnosis, and management of neurological disorders.
Join our webinar on April 27, 2023, to hear Dr. Kevin Berger share his insights on the value of using MRI quantification and lesion detection.
Attending Garmisch Symposium International 2023? Visit us at booth B8 to learn about our complete solution for the early detection, diagnosis, and management of neurological disorders.
At BioCapital Europe 2023, our CEO, Richard Hausmann, will discuss our company history and development of our cNeuro® suite.
cMRI is now available through TeraRecon's Eureka Clinical AI platform, an AI solution for imaging analysis spanning neurology, oncology, pulmonology, and cardiology.
Biomarkers, including imaging biomarkers, will be important for managing patients with Alzheimer's disease on disease-modifying drugs (DMD), such as Aduhelm and Leqembi, across the patient pathway.
Attending ECR 2023? Stop by our booth to learn about our complete solution for the early detection, diagnosis, and management of neurological disorders.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring A.M. van Gils, M. van de Beek,…
AI in radiology is here to stay. The next challenge is ensuring it’s seamlessly integrated into radiologists’ and technicians’ imaging workflows. Read about these and other takeaways from RSNA 2022 in this blog post from Richard Hausmann, CEO; Lennart Thurfjell, COO; and Greg Kingston, CMO.
New and existing tools, including cPET, cARIA, and the Dementia Differential Analysis report, extend Combinostics’ solution beyond neurological image quantification and support end-to-end workflows.